Back to search results

Brentuximab Vedotin Dosing for Mycosis Fungoides and Sezary Syndrome

This study is looking at different doses of brentuximab vedotin to see its good and bad effects in people with Mycosis Fungoides (MF), Sezary Syndrome (SS), or Lymphomatoid Papulosis (LyP). Brentuximab vedotin is a drug that is already approved for some uses. The study aims to find out if a lower dose than what is currently approved by the FDA can still be effective. You may be able to join if you are 18 or older and have been diagnosed with MF or SS that involves at least 10% of your skin, or if you have LyP. The main goal is to see how many people respond to the treatment after one year. This study plans to enroll 58 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 58 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures overall response at 1 year, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03587844

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~58 participants
Updated 2026-04-03 on ClinicalTrials.gov
What's tested:brentuximab vedotin

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
overall response
Measured over 1 year

Conditions

Mycosis Fungoides
Lymphomatoid Papulosis
Sezary Syndrome

Explore related trials

Lymphomatoid PapulosisMycosis FungoidesSezary Syndrome

NCT03587844

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Commack

    Commack, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Nassau

    Uniondale, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Westchester

    East White Plains, New Yorkstudy coordinator listed

    Recruiting

  • Stanford University Medical Center

    Stanford, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Alison Moskowitz, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Alison Moskowitz, MD
[email protected]
646-608-3726
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator.
Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator. 8. For Cohort 2, patients who previously progressed on the standard 1.8mg/kg dose and schedule of brentuximab vedotin are ineligible.
A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).

What this trial measures

  • overall response1 year

    measure best overall response during treatment by the global response score, which incorporates the mSWAT, as well as CT scan for patients with baseline nodal/visceral involvement and flow cytometry for patients with baseline positive peripheral flow cytometry